Managing Renal Dose Adjustments

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the patient's serum creatinine (most recent, ideally at steady state)? (Default: request lab)
2. What are the patient demographics: age, sex, actual body weight, height? (Default: request)
3. Is renal function stable or acutely changing (AKI)? (Default: compare SCr trend over 24-48h)
4. Is the patient receiving renal replacement therapy (HD, PD, CRRT)? (Default: verify)
5. Which medications in the patient's profile require renal dose adjustment? (Default: screen all active medications)
6. What is the patient's race/ethnicity (relevant for CKD-EPI 2021 equation)? (Default: CKD-EPI 2021 does not use race)
7. Are there factors affecting creatinine production (muscle wasting, amputation, severe liver disease, vegetarian diet)? (Default: assess)
8. What renal function estimation equation does the drug labeling use? (Default: Cockcroft-Gault for most drugs)

Documents to Request

• Serum creatinine (current and 48-72h trend), BUN
• Patient demographics: age, sex, actual body weight, height
• Cystatin C if available (for creatinine-independent GFR estimation)
• Complete medication list with doses, routes, and frequencies
• Urinalysis with albumin/creatinine ratio
• Dialysis schedule, modality, and access type if applicable
• Fluid balance and hemodynamic status
• Prior renal function baseline if available

Step 1: Estimate Renal Function

Cockcroft-Gault Equation (CrCl in mL/min) — used for DRUG DOSING:

CrCl = [(140 - age) × weight(kg)] / [72 × SCr(mg/dL)] × 0.85 (if female)

Weight selection for Cockcroft-Gault:

• Use actual body weight (ABW) if within 20% of ideal body weight (IBW)
• Use adjusted body weight if obese: AdjBW = IBW + 0.4 × (ABW - IBW)
• IBW male = 50 + 2.3 × (inches over 60)
• IBW female = 45.5 + 2.3 × (inches over 60)

CKD-EPI 2021 (eGFR in mL/min/1.73m²) — used for CKD STAGING:

• Race-free equation using age, sex, and serum creatinine
• Reports normalized to BSA (1.73 m²); may need to de-normalize for drug dosing: De-normalized GFR = eGFR × (patient BSA / 1.73)

When to use which equation:

Step 2: Identify Medications Requiring Adjustment

Screen the entire medication profile against renal dosing references. Prioritize:

High-risk drugs requiring renal adjustment (commonly missed):

Drugs to AVOID in severe renal impairment:

• Metformin (CrCl <30): lactic acidosis risk
• Meperidine: normeperidine accumulation causes seizures
• Nitrofurantoin (CrCl <30): ineffective (poor urinary concentration) and neurotoxicity
• Spironolactone with CrCl <30 and K+ >5.0: severe hyperkalemia risk
• NSAIDs in CKD 4-5: accelerate renal decline, hyperkalemia, fluid retention

Step 3: Apply Dose Modifications

Three approaches to renal dose adjustment:

1. Reduce the dose, maintain the interval:

   • Appropriate for drugs with concentration-dependent effects
   • Example: Reduce gabapentin from 300 mg TID to 300 mg BID

2. Extend the interval, maintain the dose:

   • Appropriate for drugs with time-dependent killing or prolonged effect
   • Example: Levofloxacin 750 mg q24h → 750 mg q48h

3. Both reduce dose and extend interval:

   • Appropriate for drugs with significant accumulation risk
   • Example: Acyclovir in severe CKD: reduce dose AND extend interval

For each adjusted medication, document:

• Original dose and frequency
• Renal function estimation (CrCl or eGFR with equation used)
• Adjusted dose and frequency with reference source
• Rationale for chosen adjustment strategy
• Monitoring plan (drug levels if applicable, efficacy markers, toxicity signs)

Step 4: Dialysis Dosing Considerations

Hemodialysis (HD):

• Determine if the drug is dialyzable: molecular weight <500 Da, low protein binding, low Vd → likely dialyzed
• Schedule supplemental doses POST-dialysis for drugs removed by HD
• Hold pre-HD doses that would be immediately removed

Peritoneal Dialysis (PD):

• Less efficient drug removal than HD
• Dose as for CrCl <10 mL/min for most drugs

Continuous Renal Replacement Therapy (CRRT):

• Drug clearance depends on modality (CVVH, CVVHD, CVVHDF), flow rates, and filter type
• Generally dose between CrCl 10-50 mL/min equivalence
• Use CRRT-specific dosing references (e.g., Heintz 2009 recommendations)
• Monitor drug levels when available (vancomycin, aminoglycosides)

Step 5: Monitoring and Reassessment

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was Cockcroft-Gault CrCl used for drug dosing decisions (not CKD-EPI eGFR unless drug-label specifies)?
2. Was the appropriate body weight selected (ABW, IBW, or AdjBW)?
3. Were all renally-cleared medications screened, not just the medication prompting the consult?
4. Are dialysis supplemental doses addressed for patients on RRT?
5. Is the monitoring plan specific with timeline for renal function reassessment?

Quality Audit

• Renal function estimated using Cockcroft-Gault CrCl for drug dosing purposes
• Appropriate body weight used (ABW, IBW, or AdjBW based on patient weight status)
• SCr trend assessed to determine if renal function is stable or acutely changing
• All active medications screened for renal dose adjustment need
• Dose adjustments reference drug-specific guidelines (package insert, Lexicomp)
• Contraindicated drugs in renal impairment identified and flagged
• Dialysis patients have post-HD supplemental dosing addressed
• CRRT patients have modality-specific dosing applied
• Drug level monitoring ordered for narrow therapeutic index drugs
• Electrolyte monitoring plan includes drug-renal interactions (K+ with ACEi/ARB)
• Documentation includes CrCl calculation, equation used, and weight metric
• Reassessment timeline specified for inpatient (daily SCr) and outpatient (per visit)
• Patient educated on medications to avoid (OTC NSAIDs, herbal supplements)

Guidelines

• Use Cockcroft-Gault CrCl for drug dosing unless the specific drug's labeling explicitly uses eGFR—this is a fundamental principle
• SCr alone is an unreliable indicator of renal function; a "normal" SCr in an elderly, low-muscle-mass patient may mask significant impairment
• Round CrCl up to 10 mL/min if the calculated value is <10 in a non-dialysis patient producing urine
• In AKI, creatinine is not at steady state; assume worse renal function than the calculated value suggests
• Screen ALL medications on the profile when renal function changes—not just the one that triggered the consult
• Drugs with active metabolites (morphine → M6G, meperidine → normeperidine) require special attention even if parent drug clearance seems adequate
• Do not reflexively avoid all medications in renal impairment—underdosing harms patients too; adjust, don't just stop
• Coordinate with nephrology for CRRT-specific dosing when standard references are unavailable